Connor, Clark & Lunn Investment Management Ltd.

Position in CGEM — Cullinan Therapeutics, Inc.

CIK 1596800 VANCOUVER, A1

Position in CGEM

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$5,326,424

+$1,218,100 QoQ

Shares Held

292,500

+1.2% QoQ

Ownership

0.455%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#36

of 183 holders

Holding Since

Mar 2024

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $648,992,404 across 104 Biotechnology names. CGEM ranks #29 (0.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$5,326,424	292,500	+1.2%	Shares	Sole	2026-08-13
2026-03-31	$4,108,324	289,115	+18.5%	Shares	Sole	2026-05-11
2025-12-31	$2,525,627	244,022	+75.5%	Shares	Sole	2026-02-10
2025-09-30	$824,412	139,024	+98.5%	Shares	Sole	2025-11-13
2025-06-30	$527,431	70,044	-9.8%	Shares	Sole	2025-08-07
2025-03-31	$587,590	77,621	+282.9%	Shares	Sole	2025-05-12
2024-12-31	$246,925	20,273	-44.3%	Shares	Sole	2025-02-10
2024-03-31	$620,273	36,401	—	Shares	Sole	2024-05-09
No filing history on record for this holder in this stock.